Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOXT in Borderline Resectable Pancreatic Adenocarcinoma
NCT00728000Phase 2Withdrawn
- Sponsor
- University of Cincinnati
- Start
- Aug 2008
- Primary completion
- Aug 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by University of Cincinnati. Planned start Aug 2008; status: withdrawn.
02
Drugs
oxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00728000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00728000.